It's definitely one for the long term patient holder. I believe the market is pricing in far too much risk. Management continues to manage this company exceptionally well. I would expect more MIS buy backs to bolster the company's harvest quantities over the next few years. I hope this is offered to retail investors in greater proportions than this years' raising
